Breast Cancer

A cancer survivor wonders if chemicals contributed to her breast cancer or melanoma.

In an interview with CURE, Anees B. Chagpar, from The Breast Center at Smilow Cancer Hospital at Yale-New Haven, shares her thoughts on the final guidelines and how they change the focus of screening.

Doing a little reflection about where I've been and how far I've come is just as important as making resolutions.

The cancer experience is different for all of us that is sometimes easy to navigate and sometimes not at all. Yet we all join the same team once we hear the words “you have cancer.” We can help each other to cope.

A five-year breast cancer survivor expresses uncertainty about discontinuing her hormone-suppressing medication.

"Low-income women tend to have less access to high-quality health care, along with unique needs and concerns," says Rose C. Maly.

The recommendation comes more than six years after sparking controversy over the need for annual mammograms.

A recent study has found that the majority of women at an increased risk of developing breast cancer either refuse or do not adhere to preventive treatment.

The fact that dense breast tissue can make cancers difficult to see via mammogram has been the subject of numerous recent news reports.

In a world where cancer means loss, can letting go bring peace and joy?

House Call with Len Lichtenfeld, the deputy chief medical officer of the American Cancer Society.

Staying hopeful when others are dying of the same disease is one of the most challenging aspects of cancer.

Intimacy in the life of a breast cancer survivor can be difficult, but it's not impossible.

A male breast cancer survivor recalls remarkable gifts of goodwill.

In this issue of CURE magazine, we review the current approaches for the evaluation and treatment of metastatic breast cancer, and what the future holds.

All of the women in the study had progressed on two or more HER2-targeted therapies, including Herceptin (trastuzumab) and Tykerb (lapatinib).

"We now finally have evidence that bone-targeted treatment is not only successful in treating bony metastases and preventing treatment-induced bone loss," said Michael Gnant.

After a median follow-up of 10 months, the overall response rate in patients with PD-L1-expressing metastatic breast cancer was 33.3 percent.

It's amazing how we feel the need to apologize. We want to make others comfortable. Sometimes it just doesn't work.

The DigniCap Cooling System reduces the severity and frequency of hair loss in patients receiving chemotherapy for breast cancer.

Millions of people worldwide hear these words every year.